Kobiolabs Inc. (348150) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kobiolabs Inc. (348150:KRX), powered by AI.

Current Price
₩4,130
P/E Ratio
-12.6
Market Cap
79.6B
Sector
Healthcare
What is the Kobiolabs Inc. stock price forecast?

Kobiolabs Inc. is currently trading at ₩4,130. View real-time AI analysis on Alpha Lenz.

What is Kobiolabs Inc. insider trading activity?

View the latest insider trading data for Kobiolabs Inc. on Alpha Lenz.

What is Kobiolabs Inc.'s P/E ratio?

Kobiolabs Inc.'s P/E ratio is -12.6.

Kobiolabs Inc.

KRX · 348150
₩4,130+170(+4.29%)Market closedKRX regular session 09:00–15:30 KST
Ask about Kobiolabs Inc.'s future dividend policy...
Alpha Chat Insight

Kobiolabs Inc. trades at a P/E of -12.6 (undervalued) with modest ROE of -18.0%. 3Y revenue CAGR of 81.4% highlights clear growth momentum.

Ask for details

Company Overview

Kobiolabs Inc. is a biotechnology company that specializes in developing innovative therapies and solutions aimed at addressing critical medical challenges. The company's primary function is to research and advance biopharmaceutical products that target unmet needs in the healthcare industry, focusing on areas such as oncology, rare genetic disorders, and autoimmune diseases. Kobiolabs Inc. is actively engaged in numerous clinical trials, collaborating with medical institutions and research organizations to push the boundaries of modern medicine. The significance of Kobiolabs in the market is underscored by its commitment to transforming scientific discovery into tangible health benefits, thereby contributing to the biotech sector's role in enhancing public health. Through its focus on cutting-edge research and development, Kobiolabs plays a pivotal role in the biotech industry, influencing trends and driving innovation in healthcare solutions.

CEO고광표
SectorHealthcare
IndustryBiotechnology
Employees49

Company Statistics

FY 2025

Profile

₩79,590,663,110Market Cap
₩69,291,602,990Revenue
19.27MShares Out
49Employees

Margins

73.68%Gross
-5.55%EBITDA
-13.93%Operating
-10.02%Pre-Tax
-10.06%Net

Valuation

-12.57P/E
2.46P/B
1.15EV/Sales
-27.46EV/EBITDA
-12.56P/FCF

Growth (CAGR)

81.41%Rev 3Yr
72.09%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-7.21%ROA
-18.00%ROE
-6.65%ROIC

Financial Health

₩4,593,703,040Cash & Cash Equivalents
₩37,394,798,770Net Debt
85.22%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kobiolabs Inc. (ticker: 348150) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 49 employees. Market cap is $79.6B.

The current price is ₩4,130 with a P/E ratio of -12.57x and P/B of 2.46x.

ROE is -18.00% and operating margin is -13.93%. Annual revenue is $69.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kobiolabs Inc. (348150) Stock Forecast 2026 ₩4,130 — Price, Financials & Analyst Targets | Alpha Lenz